Cipla Drug Licence Revoked Over Misleading Ads

The Maharashtra Food and Drug Administration (FDA) has revoked the carry and forwarding agent drug sale licence of Cipla Pharma & Life Sciences Ltd in Vadki, Pune. This decision follows an inspection in June of this year that revealed significant issues with Reactin Plus Tablets, a prescription medicine. The packaging and promotional materials were found to be inconsistent with the Drugs and Cosmetics Act and Rules.

Officials seized a stock of misbranded Reactin Plus Tablets valued at Rs 11.19 lakh. The FDA cited concerns that such advertisements could encourage self-medication, posing a public health risk. Cipla reportedly failed to fully comply with corrective measures after being directed to withdraw the tablets.

Further inspection identified deficiencies in the company's drug storage system, discrepancies between purchase and sales records, and differences between computerised and physical stock. Improper storage, including stock placed directly on the floor, and non-compliance with medicine recall instructions were also noted. FDA Commissioner Tukaram Mundhe emphasized zero tolerance for negligence concerning medicine safety and public health.